Spearpoint Analytics
– AI that changes prostate cancer diagnostics
ABOUT SPEARPOINT ANALYTICS
We provide patients and urologists with better decision-making information
Every year, thousands of men are diagnosed with prostate cancer based on a method that can be misleading. Should they have surgery, radiation, or wait? The decision is life-changing – and we want it to be based on the best possible analysis.
Spearpoint Analytics was founded in 2019 with a single focus: to increase the accuracy of prostate cancer diagnostics. We combine AI and clinical expertise to provide both doctors and patients with more reliable decision-making.
Our products – see what the human eye can miss
We work exclusively with prostate cancer and have developed two AI-based tools:
- PCAI (Prostate Cancer Aggressiveness Index) – An AI-based analysis that assesses the aggressiveness of the tumor and provides more accurate analysis results than traditional methods.
- SPCD (Spearpoint Cancer Detector) – An AI solution that identifies cancerous tissue in a biopsy with 98% accuracy.
Based on outcome data, the truth
.jpg)
Our AI models are developed in close collaboration with the Martini-Klinik in Hamburg, one of the world's leading clinics for prostate cancer treatment. An enormous database, 20,000 patients followed up for 20 years, has trained our AI model.
PCAI already outperforms experienced specialists in uropathology. And the model has great development potential, approaching a complete diagnostic instrument.
The future of diagnostics is here
2025 – We launch our Second Opinion service where patients can receive an AI-based analysis of their biopsy, complemented by a urologist’s assessment
2026 – PCAI becomes available to laboratories worldwide.
Reduced human suffering - saved societal costs
The goal: That all men affected by prostate cancer should receive the most accurate diagnosis possible - and thus the most adequate treatment - or, where possible, a safe message that radical treatment can wait, or even never need to be performed.
It will reduce suffering and save large societal costs.
WHO WE ARE
The Spearpoint Analytics Team
A product of international cooperation
Our partners
SPEARPOINT ANALYTICS
For investors
FOR INVESTORS
Prostate cancer diagnostics in a changing landscape
Invest in the standard of the future
Our investment round 2023, paved the way for the launch of PCAI in the Swedish market. Here we are creating a solid foundation to build the organization and secure broader expansion into the EU and the US.
With partners such as the Martini Klinik in Hamburg, one of the world's leading prostate cancer clinics, and Uppsala University Hospital, we have established credibility in the medical world. The benefits of PCAI have been highlighted in scientific articles in leading medical journals, where we have shown the technology to be superior to the older Gleason method based on human assessment.
PCAI: has concrete potential to become the new standard for decision support in prostate cancer diagnostics. With the ability to reduce unnecessary suffering through more precise treatment decisions, both physicians and, not least, patients will prefer this solution.
A huge market potential
Every year, 1.4 million men are diagnosed with prostate cancer globally, creating a need for over 2 million analyses per year. With current pricing between €400 and €1,000 per analysis, the economic opportunities are significant. Even with a marginal market share and an initially defensive pricing, to make the technology accessible to more people, the potential is favorable, and our solution is scalable to meet the demands of strong expansion.
An innovative future
Our ambition is to continue developing PCAI with research investments for even more advanced diagnostics. We also see opportunities to expand the technology to other cancer areas, further broadening the potential market and impact.
FOLLOW US ON THE JOURNEY
Welcome to participate in the next step on this exciting journey.
When the time is right for a new investment round, you are welcome as a potential investor.
Register your interest by subscribing to our newsletter and stay updated on progress and opportunities.
SPEARPOINT ANALYTICS
PCAI History
2003
Archiving ectomized prostates
Professor Guido Sauter at UKE (Universitätsklinikum Hamburg-Eppendorf). starts archiving ectomised prostates. The patients are being followed and time for recurrence and death is noted.
2008
Computerised PC grading
Professor Christer Busch starts a project with researchers from the Center for Image Analysis at UU, Uppsala University to develop a system to grade PC based on computerized image analysis.
2010
Cooperation UKE and UAS
The pathology prof Guido Sauter, UKE and prof Christer Busch, UAS (Uppsala academic hospital), starts discussing the possibility to make analysis via IT using prof Sauter's data base.
2018
AI deep learning development
Christer Busch and prof Ewert Bengtsson , identify the possibility to use the large biobank collected at Martini Klinik, UKE to train an AI to grade PC.
2018
Business investigation
Business
partner
Christer Busch starts cooperation with Peter Severgårdh , CEO, Peak Networks. Peter has more than 25 years of experience in developing, marketing and selling products in the healthcare field. Peter involves Anders Drotte 's partner.
The
goal
The goal was to develop an AI algorithm that can produce a reliable analysis that surpasses that of pathologists
Contract with
Martini Clinic
A contract is signed between Martini Klinik and Peak Networks, given Peak Networks exclusive right to use the data base for commercial purposes.
Market
definition
Questions like these where penetrated:
What is the business potential?
Who will pay for a service/product described under aim above?
How can these target groups be reached?
Pathologists, urologists and hospital CEOs were interviewed to understand the market place. and test the product idea.
Product
evaluation
Is it realistic to succeed in developing an AI algorithm that reaches the aim above?
A cooperation with IBM leads to a POC (proof of concept). The result was overwhelming.
A business term proposed by IBM was declined.
Peter Walhagen , experienced AI architect, is engaged. A new extended POC is done, confirming the realism to reach the aim.
Strategic
document
The first go/no go milestone is passed. The possibility to make the intended product is confirmed, as well as the business potential is ascertained reachable and substantial.
A continuously updated Strategic Document is produced.
2021 - 2025
PCAI Product development
2021
Developing of PCAI
The technical/medicine team, Christer Busch, Ewert Bengtsson and Peter Walhagen is developing PCAI, testing and checking.
PCAI outperforms
experts
The most important milestone is passed, when PCAI outperforms the world's leading experts within uropathology.
Approval of
research grants
Apart from the funds of €50,000, given to support product development, the approval from the state innovation authority, VINNOVA, is a confirmation of relevance and potential.
External
investor
To finance the next step of product development, an external professional investor is courted. This is another test to measure the probability of a commercial success. The expectation was also to bring business experience to the team. Herman Essén is the first external investor now an active member of the team and chairman of the board.
2022
Technical
development
Making PCAI ready for clinical use and sales
The PCAI product undergoing a validation phase. Robustness regarding different staining and scanners etc.
Getting MDR and CE approval
Medical Articles
Building user interface and clinical tests
2023
Robustness
PCAI is trimmed and developed for robustness regarding different staining, scanners, tissue thickness etc, what will be found in different lab environments.
Publication
To gain credibility, and as a ground for MDR approval, a number of publications in professional medical journals will be made.
2024
Publication
After a year of testing, trimming and development, an article is produced. It is planned to be published in a leading medical journal in Q1 2025
Clinical study
Six urologists at Uppsala Academical hospital UA have used PCAI in a pilot study. The result was overwhelming in favor of PCAI as a basis for decision compared to Gleason grading.
2025
MDR
The Medical Device Regulation (MDR) is the European equivalent of the FDA in the USA. For PCAI to be clinically used, it must undergo MDR approval, a process that takes about a year.
Market
introduction
Sales with start in 2025, targeting patients who have just been informed of suggested treatment, offering a PCAI second opinion.